Sign up to save your podcasts
Or
Share Episode 46 - Cannabis and Marijuana : Part Two
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 46 - Cannabis and Marijuana : Part Two
My sources this week were –
1. Mannila J, Järvinen T, Järvinen K, Tervonen J, Jarho P (March 2006). "Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits". Life Sciences. 78 (17): 1911–4.
2. Huestis MA (August 2007). "Human cannabinoid pharmacokinetics". Chemistry & Biodiversity.
3.Badowski ME (September 2017). "A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics". Cancer Chemotherapy and Pharmacology.
4. Nahas GG (April 2001). "The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking". Human Psychopharmacology.
5. Bridgeman MB, Abazia DT (March 2017). "Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting". P & T. 42 (3): 180–188. PMC 5312634. PMID 28250701.
6. Nahas GG, Sutin KM, Harvey DJ, Agurell S (5 April 1999). Marihuana and Medicine. Springer Science & Business Media. ISBN 978-1-59259-710
7. Osborne GB, Fogel C (2008). "Understanding the motivations for recreational marijuana use among adult Canadians" (PDF). Substance Use & Misuse. 43 (3–4): 539–72, discussion 573–9, 585–7. doi:10.1080/10826080701884911. PMID 18365950. S2CID 31053594.
8. ^ "Marijuana: Factsheets: Appetite". Adai.uw.edu. Archived from the original on 3 March 2016. Retrieved 12 July 2013.
9. Riviello RJ (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. p. 41. ISBN 9780763744625.
10. Leweke FM, Mueller JK, Lange B, Rohleder C (April 2016). "Therapeutic Potential of Cannabinoids in Psychosis". Biological Psychiatry
Thank you for listening to another episode of Macabre for mortals.
View all episodes
By Claudia BellMy sources this week were –
1. Mannila J, Järvinen T, Järvinen K, Tervonen J, Jarho P (March 2006). "Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits". Life Sciences. 78 (17): 1911–4.
2. Huestis MA (August 2007). "Human cannabinoid pharmacokinetics". Chemistry & Biodiversity.
3.Badowski ME (September 2017). "A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics". Cancer Chemotherapy and Pharmacology.
4. Nahas GG (April 2001). "The pharmacokinetics of THC in fat and brain: resulting functional responses to marihuana smoking". Human Psychopharmacology.
5. Bridgeman MB, Abazia DT (March 2017). "Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting". P & T. 42 (3): 180–188. PMC 5312634. PMID 28250701.
6. Nahas GG, Sutin KM, Harvey DJ, Agurell S (5 April 1999). Marihuana and Medicine. Springer Science & Business Media. ISBN 978-1-59259-710
7. Osborne GB, Fogel C (2008). "Understanding the motivations for recreational marijuana use among adult Canadians" (PDF). Substance Use & Misuse. 43 (3–4): 539–72, discussion 573–9, 585–7. doi:10.1080/10826080701884911. PMID 18365950. S2CID 31053594.
8. ^ "Marijuana: Factsheets: Appetite". Adai.uw.edu. Archived from the original on 3 March 2016. Retrieved 12 July 2013.
9. Riviello RJ (2010). Manual of forensic emergency medicine : a guide for clinicians. Sudbury, Mass.: Jones and Bartlett Publishers. p. 41. ISBN 9780763744625.
10. Leweke FM, Mueller JK, Lange B, Rohleder C (April 2016). "Therapeutic Potential of Cannabinoids in Psychosis". Biological Psychiatry
Thank you for listening to another episode of Macabre for mortals.